Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Equity Average (2016 - 2025)

Historic Equity Average for Integra Lifesciences Holdings (IART) over the last 16 years, with Q3 2025 value amounting to $1.0 billion.

  • Integra Lifesciences Holdings' Equity Average fell 3205.55% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 3205.55%. This contributed to the annual value of $1.6 billion for FY2024, which is 763.86% down from last year.
  • As of Q3 2025, Integra Lifesciences Holdings' Equity Average stood at $1.0 billion, which was down 3205.55% from $1.3 billion recorded in Q2 2025.
  • Integra Lifesciences Holdings' 5-year Equity Average high stood at $1.8 billion for Q4 2022, and its period low was $1.0 billion during Q3 2025.
  • Moreover, its 5-year median value for Equity Average was $1.6 billion (2024), whereas its average is $1.6 billion.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 1672.99% in 2021, then plummeted by 3205.55% in 2025.
  • Integra Lifesciences Holdings' Equity Average (Quarter) stood at $1.7 billion in 2021, then rose by 6.4% to $1.8 billion in 2022, then dropped by 10.25% to $1.6 billion in 2023, then fell by 3.16% to $1.5 billion in 2024, then crashed by 32.3% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.5 billion during Q1 2025.